(BPH or prostate cancer). "Urology Prostate Calculator: Volume and Density" app will help to estimate prostate volume and prostate specific antigen (PSA) density. Tumor volume is used, along with the Gleason Score, to prognosticate prostate cancer recurrence. PSA density helps distinguish between ...
We develop a PV calculator which is simple and accurate to be used in routine clinical consultation for LUTS patients. A separate study is important to confirm and validate the findings in other populations.doi:10.1016/j.urology.2018.02.055Lim, Jasmine...
Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone BJU Int, 103 (5) (2009), pp. 609-614 View in ScopusGoogle Scholar [26] I.M. Thompson, D.P. Ankerst, C. Chi,...
Performance Measure Calculations for High-Grade Cancer using PSA Alone, Prostate Cancer Prevention Trial Risk Calculator, Prostate Health Index (PHI), Derived Multiplex 2-Gene and 3-Gene Models, MyProstateScore (MPS), MPS2, and MPS2 Plus Prostate Volume (MPS2+) in the EDRN Validation Cohort ...
•We established and validated the CPCC risk calculator predicting biopsy result.•This risk calculator incorporated PSA, DRE result, prostate-volume, age, and free PSA ratio.•The AUC for predicting PCa and HGPCa were 0.801 and 0.826, respectively.•This risk calculator outperformed PCPT-RC...
van Vugt HA, Kranse R, Steyerberg EW, van der Poel HG, Busstra M, Kil P et al (2012) Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. Eur J Cancer 48(12):1809–1815 Article Google Scholar Alb...
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol. 2010;183(2):529-533.PubMedGoogle ScholarCrossref 99. Hernandez DJ, Han M, Humphreys EB, et al. Predicting the outcome of ...
A novel risk calculator incorporating clinical parameters, multiparametric magnetic resonance imaging, and prostate-specific membrane antigen positron emission tomography for prostate cancer risk stratification before transperineal prostate biopsy. European Urology Open Science, 53, 90–97. https://doi.org/...
et al. The management of active surveillance in prostate cancer: validation of the canary prostate active surveillance study risk calculator with the Spanish Urological Association registry. Oncotarget 8, 108451–108462 (2017). PubMed PubMed Central Google Scholar Huntley, J. H. et al. Clinical ...
We analyzed genomic data from the prostate cancer of African- and European American men to identify differences contributing to racial disparity of outcome. We also performed FISH-based studies of Chromodomain helicase DNA-binding protein 1 (CHD1) loss o